ATB 346

ATB 346 is an inhibitor of COX used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. In practice, this places the compound in experiments that measure inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses in apoptosis, cancer, and immunology models.

By inhibiting COX, ATB 346 can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The enzyme annotation adds relevance to enzyme-activity assays, substrate-conversion studies, and mechanism profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving COX
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Enzyme-activity assays, substrate-conversion studies, and mechanism profiling

Overall, ATB 346 is appropriate when a defined chemical perturbant is needed to connect COX with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.